Piper Jaffray
Piper Jaffray is a client-focused, middle market investment bank and institutional securities firm founded in 1895 and based in Minneapolis, Minnesota.
Its Investment Banking activities include raising capital through equity and debt financings for corporate clients; providing financial advisory services relating to mergers and acquisitions to consumer, financial institutions, health care, technology, alternative energy, business services, and industrial growth sectors; underwriting debt issuances for government and non-profit clients; and providing financial advisory and interest rate risk management services.
The company's equity and fixed income institutional sales and trading activities include equity and fixed income advisory and trade execution services for public and private corporations, public entities, non-profit clients, and institutional investors.
-
Human Genome (HGSI) Could Get 15% More in Takeover Bid - Analyst
-
Piper Jaffray Sees Human Genome (HGSI) Selling for $21-$26/Share in Takeover
-
Unusual 11 Mid-Day Movers 09/21: (OREX) (JASO) (HGSI) Higher; (OMEX) (TSON) (PACB) Lower
-
Human Genome (HGSI) Shares Lower Amid Concerning Benlysta Sales for July; Analyst Sees Potential Glaxo Bid at a Discount (GSK)
-
Piper Jaffray Lifts Target on Human Genome Sciences (HGSI) to $36, Maintains Overweight
-
Notable Analyst Rating Changes 09/13: KMX, NOK, HBAN, UAUA Upgraded; XOM, MA, HGSI, V Downgraded
-
Human Genome (HGSI) Slammed After BENLYSTA Fails To Hit Secondary Endpoints and European JOULFERON Application Pulled
-
Piper Jaffray Assumes Coverage on Human Genome Sciences (HGSI) with an Overweight; Benlysta's First Mover Advantage Key to $4bn+ Opportunity
-
Notable Analyst Rating Change 10/29: FITB, AET, GNW, HGSI, WYN Upgraded; GT, GCI, ATVI, FSLR, KSP Downgraded
-
Human Genome (HGSI) Up On More Takeover Talk
-
Human Genome Sciences (HGSI) Climbs Higher On Takeover Speculation
-
Piper Jaffray Reiterates an 'Overweight' Rating on Human Genome Sciences (HGSI); Optimistic About BLISS-76 Data in November
-
Analysts Still Jumping on Human Genome Sciences (HGSI) Bandwagon: 3 Upgrades Today
-
Piper Jaffray Jumps On Human Genome Sciences (HGSI) Bandwagon, Upgrades to Buy
-
Human Genome Sciences (HGSI) Surges Higher Ahead of Benlysta Data
-
JMP Securities Downgrades Human Genome Sciences (HGSI) to Market Perform
-
Piper Jaffray Downgrades Human Genome Sciences (HGSI) to Neutral; Albuferon SVR Rate Inferior to Pegasys
-
Notable Analyst Rating Changes 1/24: GILD, HGSI, Homebuilders Upgraded; BMY, EBAY, GOOG, THQI Downgraded
-
Piper Jaffray Upgrades Human Genome Sciences (HGSI) to Buy
